Mangoceuticals, Inc. (NASDAQ: MGRX) announced on March 25, 2025, its expansion into the $33 billion addressable diabetes market. The company secured exclusive rights to market and sell Diabetinol® in the USA and Canada through a Master Distribution Agreement.
Diabetinol® is a patented and clinically supported plant-based nutraceutical product. It targets the pre-diabetic and weight loss marketplace, offering a natural solution for a significant health concern.
This strategic move further diversifies Mangoceuticals' product portfolio and leverages its telemedicine platform. Gaining exclusive rights to a clinically proven product in such a large market segment represents a substantial growth opportunity for the company.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.